27 August 2024
27 August 2024
Winrevair is the first approved activin signaling pathway-targeting therapy for the treatment of the rare blood vessel disorder.
The divestiture is part of UCB’s strategy to re-align its operations with the dynamic needs of the Chinese market.
The approval is underpinned by the outcomes of the Phase III COMMODORE 2 study.
The commercial launch of AKANTIOR is set to begin in Germany in the fourth quarter of 2024.
Data from the ongoing first-in-human Phase I/II trial shows that BGB-16673 has a tolerable safety profile.
Stelara, a reference product for SteQeyma, is a biologic therapy targeting interleukin (IL)-12 and IL-23 cytokines.
The RPDD and ODD designations come with multiple benefits, including a transferrable priority review voucher.
In a trial, fulzerasib was found to be generally well-tolerated and exhibited promising antitumor activity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
